mianserin has been researched along with Neuroleptic Malignant Syndrome in 4 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 64-year-old man, diagnosed with recurrent depression, developed a neuroleptic malignant syndrome (nms) during treatment with olanzapine and mirtazapine." | 3.80 | [Electroconvulsion therapy for neuroleptic malignant syndrome]. ( Buggenhout, S; Sienaert, P; Vandenberghe, J, 2014) |
| " Antidepressant and pravastatin were administered because of the patient's abulia and hypercholesterolemia, but neuroleptic malignant syndrome-like conditions developed." | 3.71 | [Unexpected drug-interaction]. ( Tajima, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buggenhout, S | 1 |
| Vandenberghe, J | 1 |
| Sienaert, P | 1 |
| Steele, D | 1 |
| Keltner, NL | 1 |
| McGuiness, TM | 1 |
| Nisijima, K | 1 |
| Oyafuso, K | 1 |
| Shimada, T | 1 |
| Hosino, H | 1 |
| Ishiguro, T | 1 |
| Tajima, Y | 1 |
4 other studies available for mianserin and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
[Electroconvulsion therapy for neuroleptic malignant syndrome].
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Electroconvulsive Therapy; Humans; Male; | 2014 |
Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combinatio | 2011 |
Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Electroconvulsive Therapy; Female; | 1996 |
[Unexpected drug-interaction].
Topics: Aged; Amoxapine; Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Drug Interactio | 2002 |